StockMarketWire.com - Brain-gut axis treatment developer PureTech Health said it had acquired the remaining 10% of Ariya Therapeutics that it did not already own.
The company had been renamed LYT and would its four technology platforms in immuno-oncology, synthetic lymphatic targeting chemistry, milk exosomes and meningeal lymphatics.
The acquired minority interests were previously held by the co-inventors of the four platforms and associated universities and advisors.
To fund the acquisition, PureTech said it would issue 2,126,338 new ordinary shares of 1p each and grant options to the co-inventors of and advisors to the four platforms to purchase 2,147,295 ordinary shares under the PureTech Health performance share plan.
Story provided by StockMarketWire.com
Shares Magazine
Shares is the leading weekly publication for retail investors. It is packed with investment ideas, news and educational material to help build and run portfolios and get more from your money.
Investor Events
Shares puts on free Investor Events throughout the year across the country. They provide an opportunity for investors to learn more about companies on the stock market and hear from a range of investment experts including fund managers and Shares journalists.